CD8A and melanoma: Focusing on PD-L1+ EVs released by tumor and immune cells, we observed that only EVs from melanoma and CD8+ T cells resulted statistically lower levels in responders than in non-responders (Fig. 2A), in agreement with Chen’s evidences [24].